Skip to main content

Insulet Corporation Q3 FY2026 results

  • PODD · Nasdaq
  • Medical devices
  • Health Care Equipment
  • S&P 500
$152.48+2.14%Close 13 Nov 2026 · Market value $10.12B

Insulet Corporation reported revenue of $842 million, up 19.2% from a year earlier, net income of $141 million and diluted earnings per share of $2.03 against $1.24 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 4 Nov 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

Insulet Corporation Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$842.0M$706.3M+19.2%
Gross profit$632.1M$510.1M+23.9%
Gross margin75.1%72.2%+2.8 pts
Operating income$189.8M$117.7M+61.3%
Operating margin22.5%16.7%+5.9 pts
Net income$141.1M$87.60M+61.1%
Diluted EPS$2.03$1.24+63.7%
Operating cash flow$123.5M$125.7M−1.8%
Capital expenditure$57.10M$25.60M+123%
Free cash flow$66.40M$100.1M−33.7%

Operating KPIs for the quarter

Insulet Corporation operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
U.S. revenue$570.4Mup 14.7%
International revenue$266.2Mup 31.7%
Drug Delivery revenue$5.5Mdown 22.5%

Earlier quarters

Insulet Corporation results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$842.0M+19.2%$2.03
Q2 FY202630 Jun 2026$801.7M+23.5%$1.37
Q1 FY202631 Mar 2026$761.7M+33.9%$1.30
Q4 FY202531 Dec 2025$783.8M+31.2%$1.44
Q3 FY202530 Sep 2025$706.3M+29.9%$1.24
Q2 FY202530 Jun 2025$649.1M+32.9%$0.32
Q1 FY202531 Mar 2025$569.0M+28.8%$0.50
Q4 FY202431 Dec 2024$597.5M+17.2%$1.39

More on Insulet Corporation: financial statements · revenue · earnings per share

PODD's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.